Screener
Ultragenyx Pharmaceutical RARE Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
Based on the most recent quarter.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's current ratio?
- Ultragenyx Pharmaceutical (RARE) reported current ratio of 1.7× in Q2 2026.
- How has Ultragenyx Pharmaceutical's current ratio changed year-over-year?
- Ultragenyx Pharmaceutical's current ratio decreased by 29.7% year-over-year, from 2.5× to 1.7×.
- What is the long-term trend for Ultragenyx Pharmaceutical's current ratio?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's current ratio has grown at a -18.4% compound annual growth rate (CAGR), from 6.8× to 2.5×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Ultragenyx Pharmaceutical's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude